Bio-Techne Aktie

54,66USD 0,34USD 0,62%
Bio-Techne für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A12ENG / ISIN: US09073M1045

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Personal

2021 2022 2023 2024 2025
Personal am Ende des Jahres 2 600 3 000 3 050 3 100 3 100
Umsatz pro Mitarbeiter in Mio. EUR 0,36 0,37 0,37 0,37 0,39

Bilanz (in Mio. USD) - Aktiva

2021 2022 2023 2024 2025
Summe Umlaufvermögen 511 606 621 617 608
Summe Anlagevermögen 1 839 1 765 2 112 2 196 1 950
Summe Aktiva 2 350 2 371 2 734 2 813 2 558

Bilanz (in Mio. USD) - Passiva

2021 2022 2023 2024 2025
Summe Fremdkapital 779 670 767 744 639
Summe Eigenkapital 1 571 1 701 1 967 2 069 1 919
Summe Passiva 2 350 2 371 2 734 2 813 2 558

Adresse

614 McKinley Place NE, 55413-2610 Minneapolis
Telefon +1 (612) 379-8854
Internet http://www.bio-techne.com

Management

Alpna H. Seth
Independent Director
Amy E. Herr
Independent Director
Cheryl Bethune
Chief Human Resources Officer & Senior VP
David Clair
VP-Investor Relations & Corporate Development
Gary Latham
Chief Technology Officer & Vice President
James T. Hippel
Chief Financial Officer & Executive Vice President
John L. Higgins
Independent Director
Joseph D. Keegan
Independent Director
Judith Klimovsky
Independent Director
Julie L. Bushman
Independent Director
Kim Kelderman
President, Chief Executive Officer & Director
Martin Wirtz
Senior VP-Strategy & Corporate Development
Matthew F. McManus
President-Diagnostics & Genomics Segment
Qi Cheng
Vice President-Quality & Regulatory
Robert V. Baumgartner
Chairman
Roeland Nusse
Independent Director
Shane V. Bohnen
Secretary, Chief Sustainability Officer & SVP
Steven C. Crouse
SVP & GM-Analytical Solutions Division
William A. Geist
President-Protein Sciences Segment